Aytu BioPharma, Inc. (AYTU)Healthcare | Drug Manufacturers - Specialty & Generic | Denver, United States | NasdaqCM
2.25 USD
+0.01
(0.446%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.25 |
Hot Take ↕ | Aug. 22, 2026, 4:51 a.m. EDT
The immediate outlook remains heavily skewed toward caution due to a severe deterioration in the company's core business metrics. Revenue has contracted by nearly one-third year-over-year, while operating margins have collapsed into deep negative territory, indicating that the company is burning cash rather than generating value. This fundamental rot is compounded by a catastrophic multi-year price trajectory where the stock has lost virtually all of its value over the last nine years, with only a single year of recovery failing to reverse the long-term trend. While the recent price action shows a slight uptick against the 50-day average, suggesting minor technical resilience, this is insufficient to overcome the overwhelming bearish signal from the fundamentals. Furthermore, the lack of any analyst coverage and the absence of a dividend program leave investors without any safety nets or income support, making this a clear avoid for both short-term traders and long-term holders. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.035785 |
| AutoETS | 0.037958 |
| AutoARIMA | 0.037961 |
| AutoTheta | 0.088573 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 8.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.558 |
| Excess Kurtosis | -0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 65.27 |
| Revenue per Share | 6.158 |
| Market Cap | 24,149,718 |
| Forward P/E | -30.00 |
| Beta | 0.26 |
| Profit Margins | -60.17% |
| Previous Name | Aytu BioScience, Inc. |
| Website | https://aytubio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.04680848 |
| Address1 | Denver Corporate Center III |
| Address2 | Suite 920 7900 East Union Avenue |
| All Time High | 11,824,390.0 |
| All Time Low | 0.95 |
| Ask | 2.93 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 33,120 |
| Average Daily Volume3 Month | 28,475 |
| Average Volume | 28,475 |
| Average Volume10Days | 33,120 |
| Beta | 0.258 |
| Bid | 1.64 |
| Bid Size | 2 |
| Book Value | 3.274 |
| City | Denver |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.25 |
| Current Ratio | 1.123 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.2995 |
| Day Low | 2.25 |
| Debt To Equity | 65.27 |
| Display Name | Aytu BioPharma |
| Dividend Date | 1,607,472,000 |
| Earnings Call Timestamp End | 1,747,254,600 |
| Earnings Call Timestamp Start | 1,747,254,600 |
| Earnings Timestamp End | 1,747,252,800 |
| Earnings Timestamp Start | 1,747,252,800 |
| Ebitda | -2,625,000 |
| Ebitda Margins | -0.04638 |
| Enterprise To Ebitda | -7.761 |
| Enterprise To Revenue | 0.36 |
| Enterprise Value | 20,372,718 |
| Eps Current Year | -1.135 |
| Eps Forward | -0.075 |
| Eps Trailing Twelve Months | -4.59 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.2352 |
| Fifty Day Average Change | 0.014800072 |
| Fifty Day Average Change Percent | 0.0066213636 |
| Fifty Two Week Change Percent | -4.680848 |
| Fifty Two Week High | 3.07 |
| Fifty Two Week High Change | -0.81999993 |
| Fifty Two Week High Change Percent | -0.26710096 |
| Fifty Two Week Low | 1.65 |
| Fifty Two Week Low Change | 0.6 |
| Fifty Two Week Low Change Percent | 0.36363637 |
| Fifty Two Week Range | 1.65 - 3.07 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,222,349,400,000 |
| Float Shares | 7,554,998 |
| Forward Eps | -0.075 |
| Forward P E | -29.999998 |
| Free Cashflow | -1,193,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 82 |
| Fullday Change | 0.00999999 |
| Fullday Change Percent | 0.446428 |
| Fullday Price | 2.25 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.64777 |
| Gross Profits | 36,663,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.08266 |
| Held Percent Institutions | 0.35955003 |
| Implied Shares Outstanding | 10,733,208 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,672,963,200 |
| Last Split Factor | 1:20 |
| Long Business Summary | Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado. |
| Long Name | Aytu BioPharma, Inc. |
| Market | us_market |
| Market Cap | 24,149,718 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_291629081 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -34,117,000 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 24,257,050 |
| Number Of Analyst Opinions | 3 |
| Open | 2.25 |
| Operating Cashflow | 1,678,000 |
| Operating Margins | -0.32744998 |
| Payout Ratio | 0.0 |
| Phone | 720 437 6580 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.25 |
| Post Market Time | 1,787,959,806 |
| Prev Name | Aytu BioScience, Inc. |
| Previous Close | 2.24 |
| Price Eps Current Year | -1.9823788 |
| Price Hint | 4 |
| Price To Book | 0.68723273 |
| Price To Sales Trailing12 Months | 0.426681 |
| Profit Margins | -0.60169 |
| Quick Ratio | 0.854 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.446428 |
| Regular Market Day High | 2.2995 |
| Regular Market Day Low | 2.25 |
| Regular Market Day Range | 2.25 - 2.2995 |
| Regular Market Open | 2.25 |
| Regular Market Previous Close | 2.24 |
| Regular Market Price | 2.25 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 10,412 |
| Return On Assets | -0.03655 |
| Return On Equity | -0.9742 |
| Revenue Growth | -0.327 |
| Revenue Per Share | 6.158 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 10,733,208 |
| Shares Percent Shares Out | 0.03 |
| Shares Short | 321,535 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 347,011 |
| Short Name | Aytu BioPharma, Inc. |
| Short Percent Of Float | 0.0349 |
| Short Ratio | 11.69 |
| Source Interval | 15 |
| State | CO |
| Symbol | AYTU |
| Target High Price | 14.5 |
| Target Low Price | 7.0 |
| Target Mean Price | 9.5 |
| Target Median Price | 7.0 |
| Total Cash | 26,715,000 |
| Total Cash Per Share | 2.489 |
| Total Debt | 22,938,000 |
| Total Revenue | 56,599,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.3773 |
| Two Hundred Day Average Change | -0.12730002 |
| Two Hundred Day Average Change Percent | -0.053548153 |
| Type Disp | Equity |
| Volume | 10,412 |
| Website | https://aytubio.com |
| Zip | 80,237 |